A landmark international genetic study has identified 26 genomic regions linked to fibromyalgia, providing crucial evidence that the condition originates within the nervous system rather than being purely psychological or autoimmune.
A groundbreaking international genetic study has revealed 26 genomic regions associated with fibromyalgia syndrome, offering the most compelling evidence to date that this condition is rooted in the nervous system. This research, which involved data from over 2.5 million adults, was led by a team of scientists from Canada, the United States, and Finland. It highlights significant genetic overlaps with neurodegenerative diseases and other chronic pain conditions, enhancing our understanding of a complex syndrome that affects approximately 2% of the global population.
Published in the journal Nature Medicine, this extensive study is the largest of its kind, featuring contributions from 53 researchers across seven countries. The analysis included genetic data from more than 2.5 million individuals, among whom 55,000 were clinically diagnosed with fibromyalgia. The findings pinpoint specific DNA sequence variants across 26 distinct genomic regions that influence an individual’s susceptibility to the disorder. Notably, many of the genes identified in these regions are integral to nerve transmission and brain function, challenging long-standing theories about the condition’s underlying causes.
Fibromyalgia is characterized by widespread musculoskeletal pain, extreme fatigue, sleep disturbances, and cognitive impairments. For years, it has been a contentious issue within clinical medicine, often mischaracterized or dismissed due to the lack of abnormal findings in standard diagnostic imaging and blood tests.
The study’s results represent a significant shift in the understanding of fibromyalgia, moving away from historical debates about whether it should be classified as an autoimmune disease, an inflammatory condition, or a psychological disorder. Instead, it firmly establishes the syndrome’s origins in the central nervous system.
“This work changes how we think about fibromyalgia at a fundamental level,” said co-senior author Dr. Michael Wainberg, an investigator at Sinai Health’s Lunenfeld-Tanenbaum Research Institute and a professor of psychiatry at the University of Toronto’s Temerty Faculty of Medicine. “For decades, patients have been dismissed or told their pain is simply psychological. Our findings confirm the condition has a clear biological basis.”
The scale of this investigation necessitated an unprecedented cross-border collaboration, pooling data from 11 major health research initiatives across the United States, the United Kingdom, Finland, Estonia, Denmark, and Iceland. The initiative was co-led by Dr. Wainberg, Dr. Nasa Sinnott-Armstrong of the Fred Hutch Cancer Center and the University of Washington in Seattle, and Dr. Hanna Ollila of the University of Helsinki and Massachusetts General Hospital in Boston.
To determine the specific tissue types responsible for the identified risk variants, the research team integrated their genome-wide association study (GWAS) results with a comprehensive single-cell expression dataset that included 20 million individual cells from various human tissues. This multi-omic approach revealed that genes located near the 26 identified risk loci showed significantly higher expression levels in nervous system cells compared to immune, vascular, or connective tissue cells. This distinctive cellular signature sets fibromyalgia apart from traditional autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus.
Among the 26 genetic regions identified, the strongest correlation to fibromyalgia risk was linked to a variant within the HTT gene, which is known to be the primary cause of Huntington’s disease, a severe neurodegenerative disorder. Further analysis revealed another significant variant in GPR52, a G-protein-coupled receptor that regulates HTT expression levels. This receptor is currently being targeted in clinical trials for Huntington’s disease, suggesting potential avenues for drug repurposing in chronic pain management.
The study also uncovered substantial genetic overlap between fibromyalgia and several other debilitating conditions, including low back pain, irritable bowel syndrome (IBS), and post-traumatic stress disorder (PTSD). This genetic concurrence offers a biological explanation for the frequent comorbidities observed in clinical settings.
“We know that chronic pain syndromes cluster together in individuals and families and are genetically similar,” noted Dr. Frances Williams, a professor of rheumatology at TwinsUK, King’s College London, and co-author of the study. “Targeting the shared mechanisms underlying them could potentially benefit a whole cluster of disorders.”
Despite identifying these 26 genomic loci, the study emphasizes that genetics alone do not determine the onset of fibromyalgia. Instead, inherited genetic variants may create a baseline vulnerability that requires an external environmental trigger to initiate the syndrome. Such triggers could include severe physical trauma, viral infections, or localized inflammatory conditions like severe osteoarthritis.
“Understanding how genes, environmental exposures, and life events jointly contribute to the risk of fibromyalgia syndrome is critical,” explained co-senior author Dr. Sinnott-Armstrong. “Further research into the triggers of fibromyalgia and the corresponding changes to neural tissues will help us understand what drives fibromyalgia and how to treat it.”
The research team also addressed a long-standing diagnostic anomaly: while fibromyalgia is diagnosed in women approximately three times more often than in men, the genetic analysis revealed no significant differences in genetic risk architecture between the sexes. Researchers suggest that the higher clinical prevalence in females may be influenced by non-genetic factors, including hormonal fluctuations, environmental exposures, differences in central pain sensitivity, or diagnostic bias in clinical settings.
While the authors caution that these findings cannot immediately translate into a direct diagnostic blood test or instant cure, the biological mapping provides an unprecedented roadmap for therapeutic development. To further explore these findings, the study’s lead researchers have established the Chronic Pain Genomics Consortium, an international initiative focused on mapping the genetic underpinnings of other complex pain conditions, starting with chronic pelvic pain.
According to Nature Medicine, this research represents a significant advancement in understanding fibromyalgia and its biological basis, paving the way for future therapeutic strategies.